Jane Street Group, LLC Aravive, Inc. Transaction History

Jane Street Group, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.11 - $0.22 $1,419 - $2,838	12,904 New	12,904 $1,000
Q2 2023 Aug 14, 2023	SELL	$1.25 - $1.92 $29,075 - $44,659	-23,260 Reduced 37.01%	39,583 $49,000
Q1 2023 May 15, 2023	BUY	$1.29 - $2.46 $26,739 - $50,990	20,728 Added 49.22%	62,843 $125,000
Q4 2022 Feb 14, 2023	BUY	$1.2 - $1.83 $36,950 - $56,349	30,792 Added 271.94%	42,115 $55,000
Q3 2022 Nov 14, 2022	BUY	$0.61 - $1.03 $6,907 - $11,662	11,323 New	11,323 $9,000
Q3 2021 Nov 16, 2021	SELL	$3.67 - $5.8 $175,503 - $277,361	-47,821 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$4.65 - $6.42 $87,243 - $120,452	18,762 Added 64.57%	47,821 $286,000
Q1 2021 May 18, 2021	BUY	$5.11 - $9.24 $148,491 - $268,505	29,059 New	29,059 $191,000
Q4 2020 Feb 17, 2021	SELL	$4.36 - $6.51 $75,890 - $113,313	-17,406 Closed	0 $0
Q3 2020 Nov 17, 2020	SELL	$4.7 - $12.06 $3,948 - $10,130	-840 Reduced 4.6%	17,406 $82,000
Q2 2020 Aug 17, 2020	BUY	$5.18 - $14.81 $20,352 - $58,188	3,929 Added 27.44%	18,246 $212,000
Q1 2020 May 15, 2020	BUY	$3.5 - $13.77 $50,109 - $197,145	14,317 New	14,317 $83,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.